Competing interests
The PRECONNECT study was funded by Institut de Recherches Internationales, Servier, France; JT has received honoraria for speaker or advisory role from Servier, Roche, Lilly, Celgene, Shire, Amgen, Sanofi, Merck, Lilly and Sirtex; TP has received compensation for advisory board for Amgen (paid self), Merck, Roche and Takeda (paid self); LV and BC are employees of Servier; LW has received honoraria for consulting or advisory roles from Servier, and Halozyme, has served on a Speakers Bureau for Amgen and holds patents, royalties or intellectual project from Cervico, Roche, MSD, BMS; J-BB received consulting fees and lecture fees from Amgen, Bayer, Merck Serono, and Servier and lecture fees from Celgene, Roche, and Sanofi.